FDA gives emergency use authorization for Regeneron COVID-19 treatment

The Food and Drug Administration said Saturday it has awarded emergency use authorization to Regeneron Pharmaceuticals to treat COVID-19 in certain individuals.It’s approved to treat mild and moderate COVID-19 for high-risk adults and pediatric patients ages 12 and older, the FDA said.The treatment involving casirivimab and imdevimab was shown to reduce hospitalization or emergency room visits for high-risk patients.”Authorizing these monoclonal antibody therapies may help outpatients avoid hospitalization and alleviate the burden on our health care system,” FDA Commissioner Dr. Stephen Hahn said in a statement.Monoclonal antibodies — proteins made in labs — help the immune system fight off pathogens.Video: Pfizer, BioNTech seek emergency use of COVID-19 shots in USPresident Donald Trump celebrated the dose of experimental monoclonal antibodies he was given to help address his case of COVID-19. He said he thinks it helped him vanquish his coronavirus infection in record time.PCEtLSBzdGFydCBBUCBlbWJlZCAtLT4KCjxpZnJhbWUgdGl0bGU9IkRhaWx5IFVTIGNvcm9uYXZpcnVzIGNhc2VzIiBhcmlhLWxhYmVsPSJJbnRlcmFjdGl2ZSBsaW5lIGNoYXJ0IiBpZD0iZGF0YXdyYXBwZXItY2hhcnQtckJ1ZkoiIHNyYz0iaHR0cHM6Ly9pbnRlcmFjdGl2ZXMuYXAub3JnL2VtYmVkcy9yQnVmSi81LyIgc2Nyb2xsaW5nPSJubyIgd2lkdGg9IjEwMCUiIHN0eWxlPSJib3JkZXI6bm9uZSIgaGVpZ2h0PSI0MDAiPjwvaWZyYW1lPjxzY3JpcHQgdHlwZT0idGV4dC9qYXZhc2NyaXB0Ij4hZnVuY3Rpb24oKXsidXNlIHN0cmljdCI7d2luZG93LmFkZEV2ZW50TGlzdGVuZXIoIm1lc3NhZ2UiLChmdW5jdGlvbihhKXtpZih2b2lkIDAhPT1hLmRhdGFbImRhdGF3cmFwcGVyLWhlaWdodCJdKWZvcih2YXIgZSBpbiBhLmRhdGFbImRhdGF3cmFwcGVyLWhlaWdodCJdKXt2YXIgdD1kb2N1bWVudC5nZXRFbGVtZW50QnlJZCgiZGF0YXdyYXBwZXItY2hhcnQtIitlKXx8ZG9jdW1lbnQucXVlcnlTZWxlY3RvcigiaWZyYW1lW3NyYyo9JyIrZSsiJ10iKTt0JiYodC5zdHlsZS5oZWlnaHQ9YS5kYXRhWyJkYXRhd3JhcHBlci1oZWlnaHQiXVtlXSsicHgiKX19KSl9KCk7PC9zY3JpcHQ+Cgo8IS0tIGVuZCBBUCBlbWJlZCAtLT4=CNN contributed.

READ MORE  Kenya: Covid-19 - Uhuru Extends Curfew By 60 Days, Reopens Bars

The Food and Drug Administration said Saturday it has awarded emergency use authorization to Regeneron Pharmaceuticals to treat COVID-19 in certain individuals.

It’s approved to treat mild and moderate COVID-19 f or high-risk adults and pediatric patients ages 12 and older, the FDA said.

Advertisement

The treatment involving casirivimab and imdevimab was shown to reduce hospitalization or emergency room visits for high-risk patients.

“Authorizing these monoclonal antibody therapies may help outpatients avoid hospitalization and alleviate the burden on our health care system,” FDA Commissioner Dr. Stephen Hahn said in a statement.

Monoclonal antibodies — proteins made in labs — help the immune system fight off pathogens.

READ MORE  Thursday, November 12th: The Humanities Chief, Anthony Poore

Video: Pfizer, BioNTech seek emergency use of COVID-19 shots in US

President Donald Trump celebrated the dose of experimental monoclonal antibodies he was given to help address his case of COVID-19. He said he thinks it helped him vanquish his coronavirus infection in record time.

Advertisement

CNN contributed.

Source link

Be the first to comment

Leave a Reply